The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Luspatercept versus epoetin alfa in the COMMANDS trial: overall survival after two and a half years
Valeria Santini, MD, from the University of Florence, Florence, Italy, discusses an analysis of overall survival after two and a half years following the Phase III COMMANDS trial (NCT03682536), comparing luspatercept with epoetin alfa for the treatment of myelodysplastic syndromes (MDS). Prof. Santini highlights that luspatercept achieved significantly improved long-term survival in these patients. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The last data I’m showing here, in the very last day of EHA 2025, is regarding the analysis of overall survival after two and a half years of treatment, a follow-up in the COMMANDS trial, so luspatercept versus EPO. What is shown is that luspatercept gives a trend to an advantage in overall survival, 20% lower risk of death during this treatment. And what is very interesting is that the patients who survived three years, the patients who are still well and alive after 36 months, have a significantly longer survival if they receive luspatercept versus EPO...
The last data I’m showing here, in the very last day of EHA 2025, is regarding the analysis of overall survival after two and a half years of treatment, a follow-up in the COMMANDS trial, so luspatercept versus EPO. What is shown is that luspatercept gives a trend to an advantage in overall survival, 20% lower risk of death during this treatment. And what is very interesting is that the patients who survived three years, the patients who are still well and alive after 36 months, have a significantly longer survival if they receive luspatercept versus EPO. So this is the first time that we show, versus EPO, a significant improvement in long-term survival in patients who are indeed important to care for.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
